VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 57.2% in July

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 48,730 shares, a drop of 57.2% from the June 30th total of 113,911 shares. Based on an average daily volume of 11,401,344 shares, the short-interest ratio is currently 0.0 days. Currently, 1.4% of the company’s shares are short sold.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. Institutional investors own 8.23% of the company’s stock.

VivoSim Labs Stock Performance

Shares of VIVS opened at $0.42 on Monday. The company’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.53. VivoSim Labs has a 1 year low of $0.41 and a 1 year high of $5.30. The stock has a market capitalization of $1.46 million, a PE ratio of -0.08 and a beta of 1.40.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($2.21) earnings per share for the quarter. VivoSim Labs had a negative net margin of 10,567.17% and a negative return on equity of 277.62%. The business had revenue of $0.04 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings cut VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, VivoSim Labs has a consensus rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.